Given that DCs and CD8POST cells are functionally suppressed in the tumor microenvironments ofde novoand recurrent glioma patients, we tested whether anti-tumor response at the rIL-12-inflamed tumor site could be enhanced with 4-1BBL, the ligand of 4-1BB. This evidence concerns the gene TNFSF9 and central nervous system cancer.